Published in Biologics on March 01, 2007
The pathophysiology of tumor necrosis factors. Annu Rev Immunol (1992) 8.38
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc (2004) 3.40
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol (2003) 3.28
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol (2005) 3.10
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 2.80
Autoimmunity through cytokine-induced dendritic cell activation. Immunity (2004) 2.46
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet (1998) 1.94
A systematic review of treatments for severe psoriasis. Health Technol Assess (2000) 1.93
Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol (1994) 1.83
Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br J Dermatol (2000) 1.76
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol (2005) 1.72
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis (2005) 1.56
Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol (2006) 1.35
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol (2002) 1.33
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol (2005) 1.32
Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol (2004) 1.19
T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology (2004) 1.10
Overview of psoriasis. Dermatol Ther (2004) 1.04
The role of T cells in psoriasis. J Eur Acad Dermatol Venereol (2003) 0.98
Psoriasis. J Am Acad Dermatol (1984) 0.97
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol (2006) 0.91
The immunological basis of psoriasis. J Eur Acad Dermatol Venereol (2003) 0.90
The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res (2006) 0.90
A European perspective on the challenges of managing psoriasis. J Am Acad Dermatol (2006) 0.89
The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol (2006) 0.86
Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial. J Dtsch Dermatol Ges (2006) 0.83
The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life? Dermatol Ther (2004) 0.83
Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol (2006) 0.82
Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev Gastroenterol Disord (2004) 0.80
Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol (2003) 0.79
The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs (2014) 1.99
Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol (2009) 1.26
Psychosocial and societal burden of incontinence in the aged population: a review. Arch Gynecol Obstet (2007) 1.06
Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg (2005) 0.96
High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol (2003) 0.96
Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: histopathologic findings of a patient affected by multiple myeloma. Am J Dermatopathol (2004) 0.95
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases. Acta Derm Venereol (2005) 0.91
Functional skin adaptation in infancy - almost complete but not fully competent. Exp Dermatol (2010) 0.88
Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol (2008) 0.88
Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. Ann N Y Acad Sci (2007) 0.88
Incontinence in the aged: contact dermatitis and other cutaneous consequences. Contact Dermatitis (2007) 0.88
In vivo characterization of healthy oral mucosa by reflectance confocal microscopy: a translational research for optical biopsy. Ultrastruct Pathol (2013) 0.87
Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha. J Autoimmune Dis (2006) 0.86
Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol (2010) 0.86
Eosinophilic folliculitis occurring in a patient affected by Hodgkin lymphoma. Int J Dermatol (2002) 0.85
Preliminary comparison of fractional laser with fractional laser plus radiofrequency for the treatment of acne scars and photoaging. Dermatol Surg (2014) 0.84
Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatol Ther (2010) 0.84
Unilesional mycosis fungoides successfully treated with imiquimod. Eur J Dermatol (2006) 0.83
Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol Immunotoxicol (2012) 0.83
Monolateral severe eyelid erythema and edema as unique manifestation of lupus tumidus. Int J Dermatol (2005) 0.83
Neoplastic skin lesions in the elderly patient. Cutan Ocul Toxicol (2008) 0.81
Comparing in vivo reflectance confocal microscopy, dermoscopy, and histology of clear-cell acanthoma. Dermatol Surg (2009) 0.81
Topical application of preparations containing DNA repair enzymes prevents ultraviolet-induced telomere shortening and c-FOS proto-oncogene hyperexpression in human skin: an experimental pilot study. J Drugs Dermatol (2013) 0.81
Evaluation of allergic vesicular reaction to patch test using in vivo confocal microscopy. Skin Res Technol (2011) 0.80
Definition of Sensitive Skin: An Expert Position Paper from the Special Interest Group on Sensitive Skin of the International Forum for the Study of Itch. Acta Derm Venereol (2017) 0.78
The possible relevance of sex hormones on irritant and allergic responses: their importance for skin testing. Contact Dermatitis (2009) 0.78
Aging skin and food supplements: the myth and the truth. Clin Dermatol (2008) 0.78
A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients. Pediatr Allergy Immunol (2008) 0.78
Reflectance confocal microscopy of the yellow dot pattern in alopecia areata. Arch Dermatol (2011) 0.78
Terra firma-forme dermatosis. J Cutan Pathol (2013) 0.78
Blue eyes as a risk factor for type 1 diabetes. Diabetes Metab Res Rev (2011) 0.77
Eyelid dermatitis: an evaluation of 447 patients. Am J Contact Dermat (2003) 0.77
Skin moisturization and frictional effects of an emollient-treated menstrual pad with a foam core. Cutan Ocul Toxicol (2009) 0.77
Perception of disease and doctor-patient relationship experienced by patients with psoriasis: a questionnaire-based study. Am J Clin Dermatol (2009) 0.77
Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease. J Biomed Biotechnol (2012) 0.77
Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel. J Dermatolog Treat (2014) 0.76
Combined use of monopolar radiofrequency and transdermal drug delivery in the treatment of melasma. Dermatol Surg (2014) 0.76
Preliminary evaluation of in vivo reflectance confocal microscopy features of Kaposi's sarcoma. Dermatology (2010) 0.75
Efficacy of adalimumab in plaque psoriasis: experience on 28 patients. J Drugs Dermatol (2008) 0.75
Reflectance confocal microscopy for the evaluation of solitary red nodules. Dermatology (2012) 0.75
Ink spot lentigo arising on naevus spilus simulating melanoma. Acta Derm Venereol (2004) 0.75
Multiple, keratoacanthoma-like nodules on a 47-year-old man: a rare presentation of cutaneous lupus erythematosus. Int J Dermatol (2003) 0.75
In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. Arch Dermatol (2009) 0.75
Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatol Ther (2008) 0.75
Psoriasis plaque test with confocal microscopy: evaluation of different microscopic response pathways in NSAID and steroid treated lesions. Skin Res Technol (2013) 0.75
Reflectance confocal microscopy features of seborrheic dermatitis for plaque psoriasis differentiation. Dermatology (2014) 0.75
Bexarotene and interferon-alpha combination therapy in a patient affected by relapsing anaplastic large cell lymphoma with cutaneous involvement. J Drugs Dermatol (2007) 0.75
Clinical and instrumental evaluation of a cross-linked hyaluronic acid filler dermal injection: effects on nasolabial folds skin biophysical parameters and augmentation from a single-dose, monocentric, open-label trial. G Ital Dermatol Venereol (2016) 0.75
Biologic therapies for psoriasis. J Rheumatol Suppl (2009) 0.75
Salicylic acid peel incorporating triethyl citrate and ethyl linoleate in the treatment of moderate acne: a new therapeutic approach. Dermatol Surg (2013) 0.75